Contrasting BriaCell Therapeutics (OTCMKTS:BCTXF) and Aytu BioPharma (NASDAQ:AYTU)

BriaCell Therapeutics (OTCMKTS:BCTXF) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Valuation & Earnings

This table compares BriaCell Therapeutics and Aytu BioPharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BriaCell Therapeutics	N/A	N/A	-$3.68 million	($3.84)	-0.26
Aytu BioPharma	$81.00 million	0.17	-$15.84 million	($2.86)	-0.78

BriaCell Therapeutics has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for BriaCell Therapeutics and Aytu BioPharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BriaCell Therapeutics	0	0	0	0	N/A
Aytu BioPharma	0	0	0	0	N/A

Profitability

This table compares BriaCell Therapeutics and Aytu BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BriaCell Therapeutics	N/A	N/A	-786.77%
Aytu BioPharma	-19.56%	-51.31%	-12.40%

Insider and Institutional Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 2.8% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

BriaCell Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.43, meaning that its share price is 243% less volatile than the S&P 500.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

About Aytu BioPharma

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine – for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.